Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy.

Nonetheless, from 2010 onwards, it is clear from the sequential pooled cumulative meta-analyses results from studies that there is consistently and stably showed an apparent trend toward a poorer response rate to platinum-based chemotherapy treatment with advanced lung cancer patients, which range from 0.73 to 0.68 ( Fig. 5 ).

also in 709 other papers